The Department of Defense (DOD) Military Infectious Diseases Applied Research Award (MID-ARA) supports applied research to reduce morbidity and mortality from combat-related or trauma-induced wound infections. This grant aims to develop health products, approaches, or technologies for human testing. Focus areas include rapid detection of multi-drug resistant organisms (MDROs) and antimicrobial resistance, host immune response biomarkers for wound management, and preclinical testing of novel therapeutics or prophylactics for wound infection and biofilm. Preference is given to projects addressing MDROs (e.g., MRSA, A. baumannii) and invasive fungal pathogens, particularly topical treatments. The award supports hypothesis-testing, proof-of-concept, product refinement, and preclinical safety studies for IND/IDE applications. It does not fund clinical trials or fundamental basic research. Applicants must provide preliminary data and a strong scientific rationale. Collaborative Partnering PI projects are encouraged.
Opportunity ID: 231513
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-14-DMRDP-MID-ARA |
| Funding Opportunity Title: | DOD Military Infectious Diseases Applied Research Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 5 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 5 |
| Posted Date: | Apr 24, 2013 |
| Last Updated Date: | Oct 09, 2013 |
| Original Closing Date for Applications: | Sep 30, 2013 |
| Current Closing Date for Applications: | Oct 17, 2013 |
| Archive Date: | Nov 03, 2013 |
| Estimated Total Program Funding: | $11,100,000 |
| Award Ceiling: | $0 |
| Award Floor: | $0 |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | All applications MUST specifically address at least one of the MID-ARA Focus Areas related to combat-related or trauma-induced wound infections. Research projects incorporating high-throughput drug screening and/or in silico modeling, as well as applications focused on areas other than those listed below should NOT be submitted. The MID-ARA Focus Areas are: Development of new methods for rapid multi-pathogen/multi-phenotype detection of multidrug-resistant organisms (MDROs), nosocomial pathogens, and/or rapid multi-pathogen/multi-phenotype characterization of antimicrobial resistance patterns. Development of assays for host immune response biomarkers for diagnosis or prognosis (with associated outcomes) of infection to inform clinical wound management decisions (e.g., optimal wound closure time, optimal duration of antibiotics for osteomyelitis). Development and preclinical testing of novel chemotypes (chemical classes/materials), biologics as potential therapeutics or prophylactics for wound infection, and/or biofilm formation, maintenance, or propagation. Innovative treatment approaches (e.g., chelators, antibody, phage, antimicrobial peptides, quorum-sensing inhibitors, and host immunoaugmentation, etc.) are encouraged.NOTES FOR ALL FOCUS AREAS: Preference will be given to approaches that address infections with one or more multi-drug resistant organisms (MDROs), particularly, Acinetobacter baumannii, Pseudomonas aeruginosa, extended-spectrum beta-lactamase producing Enterobacteriaceae (including Escherichia coli and Klebsiella pneumoniae), and methicillin-resistant Staphylococcus aureus (MRSA), and/or invasive fungal (mold) pathogens. Preference will be given to studies leading toward topical treatments for prevention and management of wound infection. Overview: The FY14 DMRDP MID-ARA seeks applied research applications focused on the reduction of combat-related or trauma-induced wound infection morbidity and mortality. These awards are expected to yield potential health products, approaches, or technologies positioned for human testing. The intent of the FY14 DMRDP MID-ARA is to support: Hypothesis-testing and/or proof-of-concept studies in in vitro and/or in vivo models; Refinement of concepts and ideas into potential solutions with a view toward evaluating technical feasibility of emerging approaches, technologies, and promising new products; Evaluation, maturation, and/or down-selection of potential product candidates (drugs, biologic/vaccine constructs, or devices/systems) in vitro and/or in vivo and; Completion of preclinical safety and/or toxicity studies sufficient to support Investigational New Drug/Investigational Device Exemption (IND/IDE) applications.Awards may support studies with human subjects but may not be used to support clinical trials. A clinical trial is defined as a prospective accrual of human subjects where an intervention (e.g., device, drug, biologic, surgical procedure, rehabilitative modality, behavioral intervention, or other) is tested on a human subject for a measurable outcome with respect to exploratory information, safety, effectiveness, and/or efficacy. This outcome represents a direct effect on the human subject of that intervention or interaction.Awards may not be used to support fundamental basic research. Basic research is defined as research directed toward greater knowledge or understanding of the fundamental aspects of phenomena and of observable facts without specific applications toward process or products in mind.Presentation of preliminary data is required. Investigators must demonstrate logical reasoning and a sound scientific rationale established through a critical review and analysis of the literature for the application to be competitive. Research projects should include a well-formulated, testable hypothesis based on strong scientific rationale.Partnering Principal Investigator (PI) Option: The FY14 DMRDP MID-ARA mechanism supports applications that include meaningful and productive collaborations. The Partnering PIOption under this mechanism is structured to accommodate up to three PIs who will each receive a separate award. One partner is identified as the Initiating PI and the other partner(s) as the Partnering PI(s). All investigators should collaborate in the development and submission of the proposed research project. It should be clear that each investigator has a significant level of intellectual input and brings complementary strengths to the project. Multidisciplinary and multi-organizational projects are allowed. If multi-organizational, participating organizations must be willing to resolve potential intellectual and material property issues and remove any barriers that might interfere with successful completion of the research. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
301-682-5507 Email:help@cdmrp.org |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
| The archive date has been changed. | Oct 09, 2013 | |
| The closing date for receipt of applications has been extended. Please see revised Program Announcement. | Oct 09, 2013 | |
| The purpose of the modification is to extend the due date for applications. Please see revised Program Announcement. | Aug 26, 2013 | |
| A revised General Application Instructions document in being provided. | Jul 30, 2013 | |
| May 03, 2013 |
DISPLAYING: Synopsis 5
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-14-DMRDP-MID-ARA |
| Funding Opportunity Title: | DOD Military Infectious Diseases Applied Research Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 5 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 5 |
| Posted Date: | Apr 24, 2013 |
| Last Updated Date: | Oct 09, 2013 |
| Original Closing Date for Applications: | Sep 30, 2013 |
| Current Closing Date for Applications: | Oct 17, 2013 |
| Archive Date: | Nov 03, 2013 |
| Estimated Total Program Funding: | $11,100,000 |
| Award Ceiling: | $0 |
| Award Floor: | $0 |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | All applications MUST specifically address at least one of the MID-ARA Focus Areas related to combat-related or trauma-induced wound infections. Research projects incorporating high-throughput drug screening and/or in silico modeling, as well as applications focused on areas other than those listed below should NOT be submitted. The MID-ARA Focus Areas are: Development of new methods for rapid multi-pathogen/multi-phenotype detection of multidrug-resistant organisms (MDROs), nosocomial pathogens, and/or rapid multi-pathogen/multi-phenotype characterization of antimicrobial resistance patterns. Development of assays for host immune response biomarkers for diagnosis or prognosis (with associated outcomes) of infection to inform clinical wound management decisions (e.g., optimal wound closure time, optimal duration of antibiotics for osteomyelitis). Development and preclinical testing of novel chemotypes (chemical classes/materials), biologics as potential therapeutics or prophylactics for wound infection, and/or biofilm formation, maintenance, or propagation. Innovative treatment approaches (e.g., chelators, antibody, phage, antimicrobial peptides, quorum-sensing inhibitors, and host immunoaugmentation, etc.) are encouraged.NOTES FOR ALL FOCUS AREAS: Preference will be given to approaches that address infections with one or more multi-drug resistant organisms (MDROs), particularly, Acinetobacter baumannii, Pseudomonas aeruginosa, extended-spectrum beta-lactamase producing Enterobacteriaceae (including Escherichia coli and Klebsiella pneumoniae), and methicillin-resistant Staphylococcus aureus (MRSA), and/or invasive fungal (mold) pathogens. Preference will be given to studies leading toward topical treatments for prevention and management of wound infection. Overview: The FY14 DMRDP MID-ARA seeks applied research applications focused on the reduction of combat-related or trauma-induced wound infection morbidity and mortality. These awards are expected to yield potential health products, approaches, or technologies positioned for human testing. The intent of the FY14 DMRDP MID-ARA is to support: Hypothesis-testing and/or proof-of-concept studies in in vitro and/or in vivo models; Refinement of concepts and ideas into potential solutions with a view toward evaluating technical feasibility of emerging approaches, technologies, and promising new products; Evaluation, maturation, and/or down-selection of potential product candidates (drugs, biologic/vaccine constructs, or devices/systems) in vitro and/or in vivo and; Completion of preclinical safety and/or toxicity studies sufficient to support Investigational New Drug/Investigational Device Exemption (IND/IDE) applications.Awards may support studies with human subjects but may not be used to support clinical trials. A clinical trial is defined as a prospective accrual of human subjects where an intervention (e.g., device, drug, biologic, surgical procedure, rehabilitative modality, behavioral intervention, or other) is tested on a human subject for a measurable outcome with respect to exploratory information, safety, effectiveness, and/or efficacy. This outcome represents a direct effect on the human subject of that intervention or interaction.Awards may not be used to support fundamental basic research. Basic research is defined as research directed toward greater knowledge or understanding of the fundamental aspects of phenomena and of observable facts without specific applications toward process or products in mind.Presentation of preliminary data is required. Investigators must demonstrate logical reasoning and a sound scientific rationale established through a critical review and analysis of the literature for the application to be competitive. Research projects should include a well-formulated, testable hypothesis based on strong scientific rationale.Partnering Principal Investigator (PI) Option: The FY14 DMRDP MID-ARA mechanism supports applications that include meaningful and productive collaborations. The Partnering PIOption under this mechanism is structured to accommodate up to three PIs who will each receive a separate award. One partner is identified as the Initiating PI and the other partner(s) as the Partnering PI(s). All investigators should collaborate in the development and submission of the proposed research project. It should be clear that each investigator has a significant level of intellectual input and brings complementary strengths to the project. Multidisciplinary and multi-organizational projects are allowed. If multi-organizational, participating organizations must be willing to resolve potential intellectual and material property issues and remove any barriers that might interfere with successful completion of the research. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
301-682-5507 Email:help@cdmrp.org |
DISPLAYING: Synopsis 4
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-14-DMRDP-MID-ARA |
| Funding Opportunity Title: | DOD Military Infectious Diseases Applied Research Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 5 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 4 |
| Posted Date: | Oct 09, 2013 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Oct 17, 2013 |
| Archive Date: | Oct 30, 2013 |
| Estimated Total Program Funding: | $11,100,000 |
| Award Ceiling: | $0 |
| Award Floor: | $0 |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | All applications MUST specifically address at least one of the MID-ARA Focus Areas related to combat-related or trauma-induced wound infections. Research projects incorporating high-throughput drug screening and/or in silico modeling, as well as applications focused on areas other than those listed below should NOT be submitted. The MID-ARA Focus Areas are: Development of new methods for rapid multi-pathogen/multi-phenotype detection of multidrug-resistant organisms (MDROs), nosocomial pathogens, and/or rapid multi-pathogen/multi-phenotype characterization of antimicrobial resistance patterns. Development of assays for host immune response biomarkers for diagnosis or prognosis (with associated outcomes) of infection to inform clinical wound management decisions (e.g., optimal wound closure time, optimal duration of antibiotics for osteomyelitis). Development and preclinical testing of novel chemotypes (chemical classes/materials), biologics as potential therapeutics or prophylactics for wound infection, and/or biofilm formation, maintenance, or propagation. Innovative treatment approaches (e.g., chelators, antibody, phage, antimicrobial peptides, quorum-sensing inhibitors, and host immunoaugmentation, etc.) are encouraged.NOTES FOR ALL FOCUS AREAS: Preference will be given to approaches that address infections with one or more multi-drug resistant organisms (MDROs), particularly, Acinetobacter baumannii, Pseudomonas aeruginosa, extended-spectrum beta-lactamase producing Enterobacteriaceae (including Escherichia coli and Klebsiella pneumoniae), and methicillin-resistant Staphylococcus aureus (MRSA), and/or invasive fungal (mold) pathogens. Preference will be given to studies leading toward topical treatments for prevention and management of wound infection. Overview: The FY14 DMRDP MID-ARA seeks applied research applications focused on the reduction of combat-related or trauma-induced wound infection morbidity and mortality. These awards are expected to yield potential health products, approaches, or technologies positioned for human testing. The intent of the FY14 DMRDP MID-ARA is to support: Hypothesis-testing and/or proof-of-concept studies in in vitro and/or in vivo models; Refinement of concepts and ideas into potential solutions with a view toward evaluating technical feasibility of emerging approaches, technologies, and promising new products; Evaluation, maturation, and/or down-selection of potential product candidates (drugs, biologic/vaccine constructs, or devices/systems) in vitro and/or in vivo and; Completion of preclinical safety and/or toxicity studies sufficient to support Investigational New Drug/Investigational Device Exemption (IND/IDE) applications.Awards may support studies with human subjects but may not be used to support clinical trials. A clinical trial is defined as a prospective accrual of human subjects where an intervention (e.g., device, drug, biologic, surgical procedure, rehabilitative modality, behavioral intervention, or other) is tested on a human subject for a measurable outcome with respect to exploratory information, safety, effectiveness, and/or efficacy. This outcome represents a direct effect on the human subject of that intervention or interaction.Awards may not be used to support fundamental basic research. Basic research is defined as research directed toward greater knowledge or understanding of the fundamental aspects of phenomena and of observable facts without specific applications toward process or products in mind.Presentation of preliminary data is required. Investigators must demonstrate logical reasoning and a sound scientific rationale established through a critical review and analysis of the literature for the application to be competitive. Research projects should include a well-formulated, testable hypothesis based on strong scientific rationale.Partnering Principal Investigator (PI) Option: The FY14 DMRDP MID-ARA mechanism supports applications that include meaningful and productive collaborations. The Partnering PIOption under this mechanism is structured to accommodate up to three PIs who will each receive a separate award. One partner is identified as the Initiating PI and the other partner(s) as the Partnering PI(s). All investigators should collaborate in the development and submission of the proposed research project. It should be clear that each investigator has a significant level of intellectual input and brings complementary strengths to the project. Multidisciplinary and multi-organizational projects are allowed. If multi-organizational, participating organizations must be willing to resolve potential intellectual and material property issues and remove any barriers that might interfere with successful completion of the research. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
301-682-5507 Email:help@cdmrp.org |
DISPLAYING: Synopsis 3
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-14-DMRDP-MID-ARA |
| Funding Opportunity Title: | DOD Military Infectious Diseases Applied Research Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 5 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 3 |
| Posted Date: | Aug 26, 2013 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Sep 30, 2013 |
| Archive Date: | Oct 30, 2013 |
| Estimated Total Program Funding: | $11,100,000 |
| Award Ceiling: | $0 |
| Award Floor: | $0 |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | All applications MUST specifically address at least one of the MID-ARA Focus Areas related to combat-related or trauma-induced wound infections. Research projects incorporating high-throughput drug screening and/or in silico modeling, as well as applications focused on areas other than those listed below should NOT be submitted. The MID-ARA Focus Areas are: Development of new methods for rapid multi-pathogen/multi-phenotype detection of multidrug-resistant organisms (MDROs), nosocomial pathogens, and/or rapid multi-pathogen/multi-phenotype characterization of antimicrobial resistance patterns. Development of assays for host immune response biomarkers for diagnosis or prognosis (with associated outcomes) of infection to inform clinical wound management decisions (e.g., optimal wound closure time, optimal duration of antibiotics for osteomyelitis). Development and preclinical testing of novel chemotypes (chemical classes/materials), biologics as potential therapeutics or prophylactics for wound infection, and/or biofilm formation, maintenance, or propagation. Innovative treatment approaches (e.g., chelators, antibody, phage, antimicrobial peptides, quorum-sensing inhibitors, and host immunoaugmentation, etc.) are encouraged. NOTES FOR ALL FOCUS AREAS: Preference will be given to approaches that address infections with one or more multi-drug resistant organisms (MDROs), particularly, Acinetobacter baumannii, Pseudomonas aeruginosa, extended-spectrum beta-lactamase producing Enterobacteriaceae (including Escherichia coli and Klebsiella pneumoniae), and methicillin-resistant Staphylococcus aureus (MRSA), and/or invasive fungal (mold) pathogens. Preference will be given to studies leading toward topical treatments for prevention and management of wound infection. Overview: The FY14 DMRDP MID-ARA seeks applied research applications focused on the reduction of combat-related or trauma-induced wound infection morbidity and mortality. These awards are expected to yield potential health products, approaches, or technologies positioned for human testing. The intent of the FY14 DMRDP MID-ARA is to support: Hypothesis-testing and/or proof-of-concept studies in in vitro and/or in vivo models; Refinement of concepts and ideas into potential solutions with a view toward evaluating technical feasibility of emerging approaches, technologies, and promising new products; Evaluation, maturation, and/or down-selection of potential product candidates (drugs, biologic/vaccine constructs, or devices/systems) in vitro and/or in vivo and; Completion of preclinical safety and/or toxicity studies sufficient to support Investigational New Drug/Investigational Device Exemption (IND/IDE) applications. Awards may support studies with human subjects but may not be used to support clinical trials. A clinical trial is defined as a prospective accrual of human subjects where an intervention (e.g., device, drug, biologic, surgical procedure, rehabilitative modality, behavioral intervention, or other) is tested on a human subject for a measurable outcome with respect to exploratory information, safety, effectiveness, and/or efficacy. This outcome represents a direct effect on the human subject of that intervention or interaction. Awards may not be used to support fundamental basic research. Basic research is defined as research directed toward greater knowledge or understanding of the fundamental aspects of phenomena and of observable facts without specific applications toward process or products in mind. Presentation of preliminary data is required. Investigators must demonstrate logical reasoning and a sound scientific rationale established through a critical review and analysis of the literature for the application to be competitive. Research projects should include a well-formulated, testable hypothesis based on strong scientific rationale. Partnering Principal Investigator (PI) Option: The FY14 DMRDP MID-ARA mechanism supports applications that include meaningful and productive collaborations. The Partnering PI Option under this mechanism is structured to accommodate up to three PIs who will each receive a separate award. One partner is identified as the Initiating PI and the other partner(s) as the Partnering PI(s). All investigators should collaborate in the development and submission of the proposed research project. It should be clear that each investigator has a significant level of intellectual input and brings complementary strengths to the project. Multidisciplinary and multi-organizational projects are allowed. If multi-organizational, participating organizations must be willing to resolve potential intellectual and material property issues and remove any barriers that might interfere with successful completion of the research. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
301-682-5507 Email:help@cdmrp.org |
DISPLAYING: Synopsis 2
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-14-DMRDP-MID-ARA |
| Funding Opportunity Title: | DOD Military Infectious Diseases Applied Research Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 5 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Jul 30, 2013 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Sep 30, 2013 |
| Archive Date: | Oct 30, 2013 |
| Estimated Total Program Funding: | $11,100,000 |
| Award Ceiling: | $0 |
| Award Floor: | $0 |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | All applications MUST specifically address at least one of the MID-ARA Focus Areas related to combat-related or trauma-induced wound infections. Research projects incorporating high-throughput drug screening and/or in silico modeling, as well as applications focused on areas other than those listed below should NOT be submitted. The MID-ARA Focus Areas are: Development of new methods for rapid multi-pathogen/multi-phenotype detection of multidrug-resistant organisms (MDROs), nosocomial pathogens, and/or rapid multi-pathogen/multi-phenotype characterization of antimicrobial resistance patterns. Development of assays for host immune response biomarkers for diagnosis or prognosis (with associated outcomes) of infection to inform clinical wound management decisions (e.g., optimal wound closure time, optimal duration of antibiotics for osteomyelitis). Development and preclinical testing of novel chemotypes (chemical classes/materials), biologics as potential therapeutics or prophylactics for wound infection, and/or biofilm formation, maintenance, or propagation. Innovative treatment approaches (e.g., chelators, antibody, phage, antimicrobial peptides, quorum-sensing inhibitors, and host immunoaugmentation, etc.) are encouraged. NOTES FOR ALL FOCUS AREAS: Preference will be given to approaches that address infections with one or more multi-drug resistant organisms (MDROs), particularly, Acinetobacter baumannii, Pseudomonas aeruginosa, extended-spectrum beta-lactamase producing Enterobacteriaceae (including Escherichia coli and Klebsiella pneumoniae), and methicillin-resistant Staphylococcus aureus (MRSA), and/or invasive fungal (mold) pathogens. Preference will be given to studies leading toward topical treatments for prevention and management of wound infection. Overview: The FY14 DMRDP MID-ARA seeks applied research applications focused on the reduction of combat-related or trauma-induced wound infection morbidity and mortality. These awards are expected to yield potential health products, approaches, or technologies positioned for human testing. The intent of the FY14 DMRDP MID-ARA is to support: Hypothesis-testing and/or proof-of-concept studies in in vitro and/or in vivo models; Refinement of concepts and ideas into potential solutions with a view toward evaluating technical feasibility of emerging approaches, technologies, and promising new products; Evaluation, maturation, and/or down-selection of potential product candidates (drugs, biologic/vaccine constructs, or devices/systems) in vitro and/or in vivo and; Completion of preclinical safety and/or toxicity studies sufficient to support Investigational New Drug/Investigational Device Exemption (IND/IDE) applications. Awards may support studies with human subjects but may not be used to support clinical trials. A clinical trial is defined as a prospective accrual of human subjects where an intervention (e.g., device, drug, biologic, surgical procedure, rehabilitative modality, behavioral intervention, or other) is tested on a human subject for a measurable outcome with respect to exploratory information, safety, effectiveness, and/or efficacy. This outcome represents a direct effect on the human subject of that intervention or interaction. Awards may not be used to support fundamental basic research. Basic research is defined as research directed toward greater knowledge or understanding of the fundamental aspects of phenomena and of observable facts without specific applications toward process or products in mind. Presentation of preliminary data is required. Investigators must demonstrate logical reasoning and a sound scientific rationale established through a critical review and analysis of the literature for the application to be competitive. Research projects should include a well-formulated, testable hypothesis based on strong scientific rationale. Partnering Principal Investigator (PI) Option: The FY14 DMRDP MID-ARA mechanism supports applications that include meaningful and productive collaborations. The Partnering PI Option under this mechanism is structured to accommodate up to three PIs who will each receive a separate award. One partner is identified as the Initiating PI and the other partner(s) as the Partnering PI(s). All investigators should collaborate in the development and submission of the proposed research project. It should be clear that each investigator has a significant level of intellectual input and brings complementary strengths to the project. Multidisciplinary and multi-organizational projects are allowed. If multi-organizational, participating organizations must be willing to resolve potential intellectual and material property issues and remove any barriers that might interfere with successful completion of the research. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
301-682-5507 Email:help@cdmrp.org |
DISPLAYING: Synopsis 1
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-14-DMRDP-MID-ARA |
| Funding Opportunity Title: | DOD Military Infectious Diseases Applied Research Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 5 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | May 03, 2013 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Sep 30, 2013 |
| Archive Date: | Oct 30, 2013 |
| Estimated Total Program Funding: | $11,100,000 |
| Award Ceiling: | $0 |
| Award Floor: | $0 |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | All applications MUST specifically address at least one of the MID-ARA Focus Areas related to combat-related or trauma-induced wound infections. Research projects incorporating high-throughput drug screening and/or in silico modeling, as well as applications focused on areas other than those listed below should NOT be submitted. The MID-ARA Focus Areas are: Development of new methods for rapid multi-pathogen/multi-phenotype detection of multidrug-resistant organisms (MDROs), nosocomial pathogens, and/or rapid multi-pathogen/multi-phenotype characterization of antimicrobial resistance patterns. Development of assays for host immune response biomarkers for diagnosis or prognosis (with associated outcomes) of infection to inform clinical wound management decisions (e.g., optimal wound closure time, optimal duration of antibiotics for osteomyelitis). Development and preclinical testing of novel chemotypes (chemical classes/materials), biologics as potential therapeutics or prophylactics for wound infection, and/or biofilm formation, maintenance, or propagation. Innovative treatment approaches (e.g., chelators, antibody, phage, antimicrobial peptides, quorum-sensing inhibitors, and host immunoaugmentation, etc.) are encouraged. NOTES FOR ALL FOCUS AREAS: Preference will be given to approaches that address infections with one or more multi-drug resistant organisms (MDROs), particularly, Acinetobacter baumannii, Pseudomonas aeruginosa, extended-spectrum beta-lactamase producing Enterobacteriaceae (including Escherichia coli and Klebsiella pneumoniae), and methicillin-resistant Staphylococcus aureus (MRSA), and/or invasive fungal (mold) pathogens. Preference will be given to studies leading toward topical treatments for prevention and management of wound infection. Overview: The FY14 DMRDP MID-ARA seeks applied research applications focused on the reduction of combat-related or trauma-induced wound infection morbidity and mortality. These awards are expected to yield potential health products, approaches, or technologies positioned for human testing. The intent of the FY14 DMRDP MID-ARA is to support: Hypothesis-testing and/or proof-of-concept studies in in vitro and/or in vivo models; Refinement of concepts and ideas into potential solutions with a view toward evaluating technical feasibility of emerging approaches, technologies, and promising new products; Evaluation, maturation, and/or down-selection of potential product candidates (drugs, biologic/vaccine constructs, or devices/systems) in vitro and/or in vivo and; Completion of preclinical safety and/or toxicity studies sufficient to support Investigational New Drug/Investigational Device Exemption (IND/IDE) applications. Awards may support studies with human subjects but may not be used to support clinical trials. A clinical trial is defined as a prospective accrual of human subjects where an intervention (e.g., device, drug, biologic, surgical procedure, rehabilitative modality, behavioral intervention, or other) is tested on a human subject for a measurable outcome with respect to exploratory information, safety, effectiveness, and/or efficacy. This outcome represents a direct effect on the human subject of that intervention or interaction. Awards may not be used to support fundamental basic research. Basic research is defined as research directed toward greater knowledge or understanding of the fundamental aspects of phenomena and of observable facts without specific applications toward process or products in mind. Presentation of preliminary data is required. Investigators must demonstrate logical reasoning and a sound scientific rationale established through a critical review and analysis of the literature for the application to be competitive. Research projects should include a well-formulated, testable hypothesis based on strong scientific rationale. Partnering Principal Investigator (PI) Option: The FY14 DMRDP MID-ARA mechanism supports applications that include meaningful and productive collaborations. The Partnering PI Option under this mechanism is structured to accommodate up to three PIs who will each receive a separate award. One partner is identified as the Initiating PI and the other partner(s) as the Partnering PI(s). All investigators should collaborate in the development and submission of the proposed research project. It should be clear that each investigator has a significant level of intellectual input and brings complementary strengths to the project. Multidisciplinary and multi-organizational projects are allowed. If multi-organizational, participating organizations must be willing to resolve potential intellectual and material property issues and remove any barriers that might interfere with successful completion of the research. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
301-682-5507 Email:help@cdmrp.org |
Related Documents
Folder 231513 Full Announcement-2 -> fy14 mid-ara gai.pdf
Folder 231513 Full Announcement-3 -> fy14 dmrdp mid-ara pa_gg2.pdf
Packages
| Agency Contact Information: | CDMRP Help Desk 301-682-5507 Email: help@cdmrp.org |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 12.420 | PKG00174830 | Apr 24, 2013 | Oct 17, 2013 | View |
Package 1
Mandatory forms
231513 RR_SF424_1_2-1.2.pdf
231513 PerformanceSite_1_4-1.4.pdf
231513 RR_Budget-1.1.pdf
231513 RR_KeyPersonExpanded_1_2-1.2.pdf
Optional forms
231513 RR_SubawardBudget30-1.2.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
